Pipeline

Systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases.

OUR PIPELINE IS DERIVED FROM OUR ImmunoTAC PLATFORM.

We are creating molecules that are systemically delivered, tissue-directed and locally active. We are advancing a pipeline of therapies that enable new approaches for patients with chronic viral infections, cancer, and other serious diseases.

Payload

Target & Indication(s)

Preclinical Studies

Phase 1

Phase 2

PAYLOAD

SBT8230

TLR8 Agonist

TARGET & INDICATION(S)

ASGR1

Chronic Hepatitis B Virus

LEAD OP

PAYLOAD

Undisclosed

Undisclosed

TARGET & INDICATION(S)

Multiple

Preclinical

ASGR1 = Asialoglycoprotein Receptor 1 (Liver Localized Protein); TLR8 = Toll Like Receptor 8

SBT8230

Our lead virology product candidate, SBT8230, is an ASGR1-TLR8 ImmunoTAC therapeutic. SBT8230 is engineered to potently activate human myeloid cells in the liver for the treatment of chronic hepatitis (cHBV). We believe liver-localized TLR8 agonism can best realize the potential for effective therapy and potentially lead to functional cures in patients suffering from cHBV.

Additional Discovery

ImmunoTAC Conjugates

In addition to SBT8230, we are evaluating additional ImmunoTAC conjugates that modulate important disease modifying pathways in diseases with unmet medical need.

© Copyright 2022 - Silverback Therapeutics®️ | All Rights Reserved | Terms of Use